Immunogenicity of the anti-IL-17A antibody secukinumab in healthy subjects and patients

被引：0
|
作者：
Klein, U. [1 ]
Liang, E. [1 ]
Vogel, B. [1 ]
Kolbinger, F. [1 ]
Bruin, G. [1 ]
Lloyd, P. [1 ]
机构：
[1] Novartis Inst BioMed Res, Basel, Switzerland
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2013年 / 133卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
1012
引用
收藏
页码：S172 / S172
页数：1
相关论文
共 50 条
  • [31] Production, purification and biological characterization of mono-PEGylated anti-IL-17A antibody fragments
    Koussoroplis, Salome-Juliette
    Heywood, Sam
    Uyttenhove, Catherine
    Barilly, Celine
    Van Snick, Jacques
    Vanbever, Rita
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2013, 454 (01) : 107 - 115
  • [32] Onset of inflammatory bowel disease during treatment with secukinumab: Can anti-IL-17A be a trigger for inflammatory bowel disease?
    Rodriguez Moncada, R.
    Vazquez Moron, J. M.
    Rojas Feria, M.
    Herrera Justiniano, J. M.
    Maldonado Perez, B.
    Castro Fernandez, M.
    Nunez Ortiz, A.
    Cabello Rubio, V.
    Pallares Manrique, H.
    Gomez Delgado, E.
    Bejarano Garcia, A.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S502 - S502
  • [33] Response of a CARD14-associated papulosquamous eruption to the anti-IL-17A antibody ixekizumab
    Klein, Benjamin
    Treudler, Regina
    Dumann, Konstantin
    Boldt, Andreas
    Schumann, Isabell
    Simon, Jan Christoph
    Kunz, Manfred
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 3 - 3
  • [34] Neutralizing Anti-IL-17A Antibody Demonstrates Preclinical Activity Enhanced by Vinblastine in Langerhans Cell Histiocytosis
    Akefeldt, Selma Olsson
    Ismail, Mohamad Bachar
    Belot, Alexandre
    Salvatore, Giulia
    Bissay, Nathalie
    Gavhed, Desiree
    Arico, Maurizio
    Henter, Jan-Inge
    Valentin, Helene
    Delprat, Christine
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [35] Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis
    Blauvelt, Andrew
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (02) : 255 - 263
  • [36] Anti-IL-17A antibody-associated de novo vitiligo: Case report and review of literature
    Su, Hsing-Jou
    Chan, Yu-Pei
    Shen, Peng-Chieh
    Ku, Cheng-Lung
    Ng, Chau Yee
    FRONTIERS IN IMMUNOLOGY, 2023, 13
  • [37] Late Breaking Abstract - The biological pathways underlying response to anti-IL-17A (AIN457; secukinumab) therapy differ across severe asthmatic patients
    Khokhlovich, Edward
    Grant, Sarah
    Kazani, Shamsah
    Strieter, Robert
    Thornton-Wells, Tricia
    Laramie, Jason
    Morgan, Thomas
    Kennedy, Scott
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [38] Two Epitope Regions Revealed in the Complex of IL-17A and Anti-IL-17A VHH Domain
    Kostareva, Olga
    Svoeglazova, Arina
    Kolyadenko, Ilya
    Nikulin, Alexey
    Evdokimov, Stanislav
    Dzhus, Uliana
    Gabdulkhakov, Azat
    Tishchenko, Svetlana
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (23)
  • [39] Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
    Hueber, Wolfgang
    Sands, Bruce E.
    Lewitzky, Steve
    Vandemeulebroecke, Marc
    Reinisch, Walter
    Higgins, Peter D. R.
    Wehkamp, Jan
    Feagan, Brian G.
    Yao, Michael D.
    Karczewski, Marek
    Karczewski, Jacek
    Pezous, Nicole
    Bek, Stephan
    Bruin, Gerard
    Mellgard, Bjoern
    Berger, Claudia
    Londei, Marco
    Bertolino, Arthur P.
    Tougas, Gervais
    Travis, Simon P. L.
    GUT, 2012, 61 (12) : 1693 - 1700
  • [40] β-defensin-2 (BD-2) responds to a single dose of anti-IL-17A secukinumab in different skin layers of psoriatic patients within days
    Loesche, C.
    Kolbinger, F.
    Valentin, M. -A.
    Jarvis, P.
    Cheng, Y.
    Bruin, G.
    Polus, F.
    Aigner, B.
    Bodenlenz, M.
    Sinner, F.
    Pieber, T. R.
    Patel, D. D.
    EXPERIMENTAL DERMATOLOGY, 2016, 25 : 37 - 38
12345